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Abstract
Background: Anorexia Nervosa (AN) is a serious, debilitating condition that causes significant physical, emotional, and
functional impairment. The condition is characterized by destructive weight loss behaviours and a refusal to maintain body
weight at or above a minimally normal weight for age and height. AN often develops in adolescence and is a predominantly female
disorder. Treatment for AN typically involves medical, nutritional and psychological interventions. Pharmacotherapy is also often
used; however, the literature on the effectiveness of these drugs in a pediatric population is very limited. Olanzapine, which is
an 'atypical' antipsychotic, is becoming more widespread in the treatment of AN. Olanzapine is hypothesized to facilitate weight
gain, while decreasing levels of agitation and decreasing resistance to treatment in young women with AN. This randomized,
double-blind placebo-controlled trial seeks to examine the effectiveness and safety of olanzapine in female youth with AN.
Methods/Design: Adolescent females between the ages of 12 and 17 diagnosed with AN (either restricting or binge/purge
type) or Eating Disorder Not Otherwise Specified with a Body Mass Index of less than or equal to 17.5, will be offered inclusion
in the study. Patients will be randomly assigned to receive either olanzapine or placebo. Patients assigned to receive olanzapine
will start at a low dose of 1.25 mg/day for three days, followed by 2.5 mg/day for four days, 5 mg/day for one week, then 7.5
mg/day (the target dose chosen) for 10 weeks. After 10 weeks at 7.5 mg the medication will be tapered and discontinued over
a period of two weeks. The effectiveness of olanzapine versus placebo will be determined by investigating the change from
baseline on measures of eating attitudes and behaviors, depression and anxiety, and change in Body Mass Index at week 12, and
after a follow-up period at week 40. It is anticipated that 67 participants will be recruited over two years to complete enrollment.
Discussion: Randomized controlled trials designed to measure the safety and effectiveness of olanzapine in comparison to
placebo are desperately needed, particularly in the adolescent population.
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Background
The current knowledge of Anorexia Nervosa (AN) indi-
cates that it is a complex, serious, and often-chronic con-
dition characterized by an interplay of debilitating
cognitive, emotional and physical processes, and destruc-
tive weight loss behaviors. The diagnostic criteria for AN
consists of a refusal to maintain body weight at or above
a minimally normal weight for age and height; an intense
fear of gaining weight or becoming fat; a disturbance in
the way in which one's body weight or shape is experi-
enced, and in post-menarchal females, the absence of at
least three consecutive menstrual cycles [1]. AN often
develops in adolescence and is found to be most prevalent
in youth, with the age of onset typically peaking between
15 and 19 years [2]. Lucas and colleagues [2] reported
incidence rates of AN in the northern United States to be
25.7 females and 3.7 males per 100,000 of the population
per year in the 10 to 14 year old age group, and 69.4
females and 7.3 males with AN per 100,000 of the popu-
lation per year in the 15 to 19 year old age group. Cur-
rently, at the Children's Hospital of Eastern Ontario
(CHEO), we treat on average 60 new eating disorder
patients per year, 20 of whom would require hospitaliza-
tion due to medical instability from AN.
Development of AN predisposes children and adolescents
to a number of potentially harmful physical and emo-
tional sequelae. Adverse physical effects related to pro-
found weight loss and starvation include bradycardia,
hypotension, hypothermia, dehydration, cardiac arrhyth-
mias, heart failure, kidney failure, pancreatitis, amenor-
rhea, osteopenia, neurological impairments, and
hormonal imbalances [3]. Prolonged illness can also
result in impairments in long-term growth, bone density
and fertility [4]. Psychological sequelae of AN include
depression, suicidality, mood lability, social withdrawal,
cognitive impairment, insomnia, irritability, agitation,
and marked deterioration in family relationships [5]. Sul-
livan [6] reported mortality rates in individuals with eat-
ing disorders that exceeded the expected incidence of
death from all causes in women 15 to 24 years of age by
12-fold. Many adolescents diagnosed with AN have diffi-
culties functioning at school or with their peers resulting
in increased isolation and social withdrawal.
Current treatment of AN involves a multidisciplinary
approach. This includes medical and nutritional rehabili-
tation as well as psychological interventions [7]. There
have not been any large randomized trials showing effi-
cacy of any one pharmacological agent for the treatment
of AN to date. A recent prospective study suggested that
eating disorders are very difficult to treat with only 30% to
50% of patients fully recovering from the illness after six
years [8]. There is evidence to suggest that patients that
present with an extended preceding history of anorexic
behaviour are more difficult to treat and cure and that
early interventions improve prognosis [5]. Psychotropic
medications such as antidepressants and antipsychotics
have been investigated for the treatment of eating disorder
patients either in addition to or instead of psychologically
based treatment [9]. A recent review on the use of pharma-
cotherapy in the treatment of AN indicated that antide-
pressant use showed no benefit when compared to
standard care [10]. Hence, antidepressant medications are
not recommended as a first line treatment for AN,
although there is some limited evidence suggesting a
potential role for antidepressants in maintenance treat-
ment of weight-recovered patients [11]. Antipsychotic
medications such as chlorpromazine and pimozide have
also been investigated as adjunctive treatment options for
AN [10]. These medications have been associated with sig-
nificant short-term and long-term side effects, and have
not been found to be helpful in changing attitudes
towards eating behaviour or body image. Long-term
improvements in outcome in those treated with these
medications are also lacking. For these reasons, the risks
of using these particular medications are felt to outweigh
any potential benefit. [10,12]
More recently, newer "atypical" antipsychotic medica-
tions such as olanzapine have been investigated as a pos-
sible treatment option for patients with AN. Olanzapine is
a thienobenzodiazepine which has been studied exten-
sively for the treatment of schizophrenia, and which more
recently has been indicated for the treatment of bipolar
disorder. Its mechanism of action is assumed to lie in its
ability to block dopaminergic and serotonergic receptors
(D1-4 antagonism and 5 HT 2A/2C antagonism). Small
case reports and case series have shown some evidence of
success using this medication for the treatment of AN; suc-
cess in the short term being indicated bypatients increased
BMIs, decreased levels of anxiety regarding food, and a
decrease in ruminating thoughts surrounding food and
body concerns[13,14]. Additionally, the side effect profile
of atypical antipsychotics such as olanzapine may be
more favorable than older antipsychotics [12]. Antipsy-
chotic medications are hypothesized to reduce anxiety
and agitation, as well as mitigating obsessions or delu-
sions regarding weight and body shape [15]. Moreover,
these types of medications have been linked to increased
weight gain in other psychiatric populations, although the
exact mechanism for this remains unclear [16,17].
In recent reviews of pharmacology and eating disorders,
antipsychotic medications have demonstrated promise in
the treatment of eating disorders. In spite of reported clin-
ical success [14,18-20], and open trials: [21,22]), we are
only aware of two published randomized controlled trials
(RCT) which have evaluated the effectiveness of olanzap-
ine [23,24]. The first of RCT contained a very small sampleBMC Pediatrics 2008, 8:4 http://www.biomedcentral.com/1471-2431/8/4
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of adult patients with AN and compared the effects of
olanzapine against chlorpromazine in reducing anorexic
patients ruminating thoughts. Olanzapine was shown to
be more effective than chlorpromazine in decreasing
ruminative anorectic cognitions [23]. The second RCT
investigated the effects of adding olanzapine treatment
(randomized double blinded design) to patients partici-
pating in cognitive behavioral therapy. The number of
patients in this study was also low, but psychological
improvements were significant in the olanzapine group
compared to the control group in specific cognitive
domains. BMI's also significantly increased in the ano-
rexic population with binge/purge subtype compared to
the control group [24]. In recent case reports, olanzapine
has been associated with considerable weight gain and
maintenance, clinically notable decreases in levels of agi-
tation, and improvements in sleep [14,18], general func-
tioning, and overall compliance with treatment in
children and adolescents diagnosed with AN [18,25,26].
Despite the lack of much empirical evidence, antipsy-
chotic medications such as olanzapine are now widely
used in the treatment of severe eating disorders. Recent
case reports have demonstrated that olanzapine may be
associated with marked improvements in weight gain,
along with decreased anxiety and agitation, decreased
obsessionality, and decreased resistance to treatment
[14,18-22,25,26]. However, olanzapine will remain clas-
sified as an 'experimental' drug rather than a recom-
mended and accepted treatment for AN, until safety and
efficacy can be established in this population using a high
quality randomized trial.
It is hypothesized that adolescents who are diagnosed
with a severe eating disorder and are treated with olanza-
pine will demonstrate reduced disordered eating attitudes
and behaviours as well as an increased rate of weight gain,
as compared to a control group treated with placebo. It is
also hypothesized that patients treated with olanzapine
will demonstrate better long-term clinical outcomes in
comparison to patients treated with placebo. It is also pre-
dicted that the adverse effects of olanzapine will be minor
given the relatively low dose (as compared to treatment
for patients with schizophrenia), slow titration, and short-
term use of olanzapine.
Methods/Design
This study is a randomized, double-blind, placebo-con-
trolled trial. The ethics committee at the Children's Hos-
pital of Eastern Ontario has approved the study protocol.
Study Population
Adolescent females living within Eastern Ontario, Can-
ada, who are between the ages of 12 and 17 and have been
diagnosed with AN (either restricting or binge/purge type)
or Eating Disorder Not Otherwise Specified (EDNOS)
with a BMI of less than or equal to 17.5, will be offered
participation in the study. Adolescents with a diagnosis of
EDNOS and a low BMI are included as it is recognized
that though not necessarily meeting all of the criteria for
Anorexia Nervosa (see inclusion criteria), these two diag-
noses are conceptualized similarly in terms of develop-
ment and treatment.
Trial Design
A randomized, double-blind, placebo-controlled design
will be used to determine the efficacy and safety of olan-
zapine in treating AN. Consecutive female patients diag-
nosed with a severe eating disorder, who meet eligibility
criteria, and who consent to participate in the study, will
be randomly assigned to one of two groups: olanzapine
(OLA) or placebo (PLA). A medication schedule will be in
place for a total of 14 weeks (see Table 1 for Schedule of
Events). Medication will be started at a low dose and
increased up to a predetermined maximum dose, or until
an intolerable side effect occurs. Both groups will receive
either olanzapine or placebo for a total of 14 weeks. Both
groups will continue to receive standard care that includes
psychological, nutritional, and medical treatment.
Assessment Process
Screening of participants for inclusion criteria and exclu-
sion criteria will take place at the time of initial assess-
ment. The assessment consists of a full day, during which
patients complete psychological measures (see Table 1)
and undergo psychiatric, nutritional, and medical assess-
ments. After completing a variety of psychological meas-
ures, the patient will be interviewed by members of the
treating team. A psychiatrist or a psychologist along with
a medical doctor will conduct the initial interview. Fol-
lowing the interview, the patient then completes a nutri-
tional assessment with a registered dietician. During this
time, the patient's parents are also interviewed. The med-
ical assessment consists of a physical examination, along
with documentation of vital signs (temperature plus lying
and standing heart rate and blood pressure), and labora-
tory tests (see Table 1). After the formalized assessment is
complete, determination of the patient's eligibility for the
outlined study is determined.
Inclusion Criteria
To be eligible to participate in this trial, candidates must
meet the following inclusion criteria at screening:
1. Patient must be female
2. Patient and one parent must give written informed
Consent or Assent.B
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Table 1: Schedule of Events
Timelines + 3 days Day -7 Day 0 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56 Day 63 Day 70 Day 77 Day 84 Day 91 Day 98 Day 105 Day 280+ 7
VISIT Screen Week 0 Rand Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13 Week 14 Week 15 or Term Week 40 F/UP
Informed Consent x
Medical History x
Demographics x
Inclusion/Exclusion x x
Height x xx
W e i g h t  &  B M I  s c o r e x x xxxxxxxxx xxxxx x x
Physical Exam x x
Randomization x
V i t a l  S i g n s x x xxxxxxxxx xxxxx x x
Hematology & Chemistry* x x x x x x
HBA1C x x
M u l t i s t i c k  U r i n a l y s i s x x xxxxxxxxx xxxxx x
U r i n e  f o r  P r e g n a n c y x x xxxxxxxxx xxxxx x
Electrocardiogram (EKG) x x x x
A d v e r s e  E v e n t s xxxxxxxxx xxxxx x x
Concomittant Meds (mg) x 1.25 → 2.5 5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 5.0 2.5 0 0 0
D i s p e n s e  S t u d y  M e d x xxxxxxxxx xxxx
A I M S xxxxxxxxx xxxxx x
Psychological Measures
EAT-26 x x x x x
CDI ** x x x x x
MASC ** x x x x x
CAPI x x x x x
CBCL** x x x x x
EDS3 x x x x x
*namely CBC and diff, electrolytes, Mg, Ca, P04, BUN, Cr, fasting glucose, Albumin, Ferritin, vit.B12, RBC folate, FSH, LH, estradiol, prolactin, βHCG, TSH, INR, cholesterol and triglycerides, ALT, AST and Alk. Phos. If more than 2 weeks 
have elapsed between Screen labs and Baseline (week 0), repeat Screen labs work prior to or at Baseline Visit (with the exception of bone mineral density)
** If CDI, MASC and CBCL have been completed at Screen Visit and it is < 2 weeks, these measures may not be repeated at week zero.BMC Pediatrics 2008, 8:4 http://www.biomedcentral.com/1471-2431/8/4
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3. Must be between ages of 12 and 17 (younger than 18)
at beginning of Trial.
4. Based on the Diagnostic and Statistical Manual of Men-
tal Disorders IV [1] must have fulfilled the criteria for
diagnosis of Anorexia Nervosa (of which there are two
types: restricting type or binge-eating/purging type) or
Eating Disorder Not Otherwise Specified, with a Body
Mass Index of less than or equal to 17.5.
Exclusion Criteria
Candidates will be excluded from trial entry if any of the
following exclusion criteria exist at screening:
1. Known sensitivity to any of the products to be adminis-
tered.
2. Currently receiving treatment with any other anti-psy-
chotic medication, mood stabilizer, or stimulant.
3. Treatment with medication known to interact with
olanzapine, (eg. Fluvoxamine, Ciprofloxacin).
4. Known diagnosis of: diabetes, impaired glucose toler-
ance, hyperlipidemia, hepatic dysfunction, substance
abuse, narrow angle glaucoma, paralytic ileus, or pancre-
atitis, or any other medical illness that would be consid-
ered to significantly impact treatment or recovery from
AN
5. Inability to comply with trial requirements including
lack of comprehension of English.
6. Pregnant or breast-feeding.
7. Other unspecified reasons that, in the opinion of the
Investigator, make subject unsuitable for enrollment.
Laboratory exclusion criteria:
• Total white cell count < 2.5
• Neutrophil count < 1.0
• Liver function tests (AST/ALT > 2× normal)
• Positive pregnancy test
• EKG – QTc > 440 msec or arrythmia other than sinus
bradycardia; conduction
abnormalities prolonged QTc or other
Consent and Enrollment
When the adolescent meets inclusion and not exclusion
criteria, the physician or psychiatrist will provide the
patient and her family with a brief description of the
study, the extent and implications of adolescent and
parental involvement, and the overall purpose of the
research study. The adolescent and family will be asked to
consider involvement in the study and permission will be
requested for a follow-up phone call from the project
coordinator within the next 72 hours. As well, a meeting
with the study psychiatrist will be offered during which
the nature of the study will be described in greater detail
and questions will be answered. The family will be reas-
sured that they will continue to receive standard care
regardless of their involvement in the study.
The project coordinator will read through the assent and
consent forms with the patient and her parent(s), have all
members sign, and will provide them with their first
scheduled visit (see Table 1 for Schedule of Events). It is
expected that most patients who consent will be enrolled
into the study within two weeks of their initial assessment
(screening visit). If, however, more than two weeks have
elapsed since the screening visit, their baseline blood
work, urinalysis, weight, height, vital signs and EKG will
be repeated (but not bone mineral density).
The consent of only one parent will be required. Adoles-
cents whose parent(s) consent to the study, but who
themselves do not assent or consent, will not be included
in the study and in no way will this compromise their
care.
Randomization Procedures
Participants, having provided the appropriate consent, are
to be enrolled at Visit 1, after all baseline evaluations have
been completed. Participants will be randomized (1:1
ratio) to olanzapine or placebo using a computer gener-
ated block-size randomization schedule. To help ensure
adequate allocation concealment, the computer-gener-
ated sequence will be kept centrally at the Chalmers
Research Group (CRG) on computer and can only be acti-
vated when there is an eligible participant to randomize.
The research coordinator will complete an eligibility crite-
ria checklist using a 24/7-telephone randomization sys-
tem. Upon receipt of an affirmative answer of the
participant eligibility, the system will release a randomiza-
tion number that will correspond to a bottle of medica-
tion stored in pharmacy.
Blinding Procedure
All personnel at the investigational site will be blinded to
the treatment except for the Pharmacist (or designee). The
participant and her parents will also be blinded in a simi-
lar fashion. The look-a-like placebo will be dispensed inBMC Pediatrics 2008, 8:4 http://www.biomedcentral.com/1471-2431/8/4
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identical bottles to the experimental medication. The
research pharmacist will be responsible for labelling the
medication with the participant's randomization number
and placing the required dose for the 14-week treatment
period. Only the pharmacist will be aware of the randomi-
zation sequence and that sequence will not be broken
until analysis of the results is completed. The sequence
may only otherwise be broken if requested by the inde-
pendent Data Safety and Monitoring Committee
(DSMC). The statistician will also be blinded to the
groups when managing data sets.
Dose Rationale
The recommended dose of olanzapine for treating psy-
chosis in adult patients with schizophrenia is 5–20 mg/
day, with doses of 30–40 mg/day not uncommon in clin-
ical practice [27]. A study currently underway at the
Ottawa Hospital (General Campus) to evaluate the effi-
cacy and safety of olanzapine for the treatment of adults
with AN used 5 mg of olanzapine as a starting dose, and
increased to 10 mg/day (Dr. H. Bissada, personal commu-
nication, September, 2004).
The dosing regimen to be used for the outlined study has
been derived from both current clinical practice parame-
ters and available literature. Low doses of olanzapine
(2.5–5.0 mg daily) are typically prescribed for the treat-
ment of children and adolescents with severe eating disor-
ders. In older or more agitated patients the dose may be
increased to 7.5 mg or even 10 mg per day. These doses are
typically well tolerated, with sedation as the main noted
side effect. In anticipation of this trial, members of the
American Academy for Eating Disorders were polled
through the online email service ("AED listserv") regard-
ing their dosing of olanzapine in clinical practice. The
results of this poll revealed a wide range in the dosing of
olanzapine, from 1.25–20 mg/day.
With the above guidelines in mind, olanzapine will be ini-
tiated at the lowest dose available by tablet formulation
(1.25 mg). The medication will be slowly increased over a
two-week period assuming patient tolerance to a maxi-
mum dose of 7.5 mg/day (1.25 mg/day for three days, fol-
lowed by 2.5 mg/day for four days, 5 mg/day for one
week, and then the target dose of 7.5 mg/day for 10
weeks). After a period of 10 weeks at 7.5 mg, the medica-
tion will be tapered and discontinued over a further two
weeks. Table 1 outlines the exact dose schedule as part of
the trial schedule.
Psychological Measures
Patients' psychological well-being will be measured utiliz-
ing the following six scales:
Eating disorder symptoms will be measured using the Eat-
ing Attitudes Test (EAT-26) [28], the EAT-26 is a 26-item
self-report questionnaire with a 6-point scale that meas-
ures 3 domains of disordered eating: dieting, bulimia and
food preoccupation, and oral control. The EAT-26 is a
widely used, well-validated instrument in this clinical
population. In this study, the total EAT-26 score will be
used.
Psychiatric Symptoms will be measured using the Chil-
dren's Acuity of Psychiatric Illness Scale-Child and Ado-
lescent (CAPI) [29], The CAPI is an outcome measure for
children and adolescents that is designed to monitor
change deriving from contact with mental health services.
The CAPI yields a total raw score and four subscale scores,
including Risk Factors, Symptoms, Functioning, and Sys-
tems support. The scale has good inter-rater reliability
(.78 to .85) and good internal consistency (.87) across a
variety of settings [29].
Depressive symptoms will be measured using the Chil-
dren's Depression Inventory (CDI) [30]. The CDI is a 27-
item questionnaire, which asks respondents to endorse
statements about themselves reflecting cognitive, behav-
ioural and somatic symptoms of depression. Items are
rated on a 3-point scale indicating symptom severity.
Total scores on the CDI can range from 0 to 52, with
higher scores indicating higher levels of depressive symp-
tomatology. The measure has been shown to have accept-
able internal consistency (alphas = .71 to .89) as well as
good discriminant validity when classifying children with
no significant psychopathology versus depressed children
[30]. The total score of the CDI will be used in this study.
Anxiety symptoms will be measured using the Multidi-
mensional Anxiety Scale for Children (MASC) [31]. The
MASC is a 39-item 4-point Likert-style self-report which
demonstrated a satisfactory to excellent range for the
intraclass correlation coefficient for the three subscales:
physical symptoms, harm avoidance, and social anxiety in
a sample of youth (ICC = 0.79 to 0.92) [32]. The total
score on the MASC will be used in this study.
Clinicians will be asked to complete the Eating Disorder
Symptom Severity Scale (EDS3) [33] which will examine
their observations of the youth's eating disorder symp-
toms such as: dieting behaviours, body image preoccupa-
tions, agitation related to eating/body image, fear of fat,
food anxiety, as well as overall motivation for treatment.
Clinicians involved in the study have attended a work-
shop meant to improve inter-rater reliability for this scale
(r = .75 to r = .80 was deemed acceptable)
Parents will be asked to complete the Child Behavior
Checklist [34] in order to evaluate their perceptions ofBMC Pediatrics 2008, 8:4 http://www.biomedcentral.com/1471-2431/8/4
Page 7 of 9
(page number not for citation purposes)
their child's mood and anxiety. The Child Behaviour
Checklist (CBCL) has been demonstrated to be a reliable
measure when completed by parents, with a mean alpha
0.80 being reported [34]. The CBCL is a widely used, well-
validated instrument in pediatric populations.
The psychological measures will be completed at baseline,
weeks 6, 12, 15 and 40 (see Table 1). The patient will com-
plete the EAT, CDI and the MASC; the parent will com-
plete the CBCL; and the treating physician and therapist
will complete the CAPI and EDS3.
Medical Monitoring (see Table 1 for Schedule of Events)
The baseline medical assessment will include a physical
examination, monitoring of side effects/symptoms (uti-
lizing the side-effect checklist), completion of the
Acquired Involuntary Movement Scale (AIMS) to monitor
extrapyramidal symptoms, taking of vital signs (tempera-
ture plus lying and standing heart rate and blood pres-
sure), an EKG, bone mineral density, and comprehensive
lab work (see Table 1). An EKG will be repeated at Weeks
2, 4, and 15. At each clinic visit, a urine sample (urinalysis
and pregnancy test) will be taken, vital signs completed,
and weight recorded.
The AIMS and an adverse event checklist are also com-
pleted at each clinic visit.
Primary Outcome Measures
The primary outcome measure will be the change from
baseline on the total score of the EAT-26 score measured
at week 12 prior to topping off the medication, and BMI
change over the first 12 weeks of treatment.
Secondary Outcome Measures
Change from baseline in the EAT-26 score measured at
week 6, 15 (i.e. off medication) and at the end of the
maintenance period (week 40), as well as BMI change
measured at the same time points will be analyzed as for
the primary outcomes. Change from baseline in the CAPI,
the CDI, the MASC, the EDS3 and the CBCLwill be calcu-
lated for weeks 6, 12, 15 and 40.
Discussion
Safety Issues
At each visit, the patient will be asked about any harm
they may have experienced and clinical assessments will
be performed to determine the safety of olanzapine. All
adverse events will be recorded on the Case Report Form
(CRF) and entered into the database. Harms include any
untoward medical occurrence that a study participant
experiences, whether or not that event is considered to be
in relation to the study drug. Serious adverse events
(SAE's) are those events that result in death or are life
threatening, result in hospitalization or prolongation of
hospitalization, result in persistent or significant disabil-
ity, or result in a congenital birth defect. All SAE's will be
reported to Health Canada as per the required reporting
timelines. As well, all SAE's will be reported to an inde-
pendent Data Safety and Monitoring Committee
(DSMC).
If a patient endorses Item "9" "I want to kill myself" on
the Child Depression Inventory (CDI), the project coordi-
nator will immediately contact the Research Investigator
and establish a plan to assess risk for suicide. The project
coordinator will survey the item immediately after the
adolescent completes the questionnaires.
Sample Size
Given the relative novelty of this application of olanzap-
ine, no formal evaluation of the drug has yet been con-
ducted on youth, making it difficult to accurately estimate
sample size requirements. However, after consultation
within our clinical team we believe that a decrease of 5
points on the EAT-26 scale would be clinically meaning-
ful. The following assumptions were therefore used for
sample size calculations: i) a minimal clinical important
difference of 5 on the EAT-26 score; ii) an estimated stand-
ard deviation of 7.07; iii) two-sided test; iv) a power of
80% and a type I error of 5%; v) a provision for one
interim analysis according to the O'Brien and Fleming cri-
teria [35]. With these assumptions, the total sample size
necessary is 64 participants. Anticipating a drop-out rate
of at most 2.5%, the formula of Donner [36] may be used
to adjust the sample size assuming an intention to treat
analysis. The resulting total sample size is thus 67 partici-
pants (33 and 34 participants per treatment group). We
anticipate that this study will take two years to complete
enrollment.
Statistical Analysis
Descriptive summaries of demographic and treatment
balance will be generated with respect to all participant
characteristics at baseline. Dichotomous variables will be
summarized using percentages, normally distributed con-
tinuous variables will be summarized using means
together with standard deviations, and continuous varia-
bles that are not normally distributed will be summarized
using medians together with range.
Statistical analysis of the data will follow the intention-to-
treat principle for the main analysis of treatment out-
comes. For participants who develop clinical events that
will lead to withdrawal from the study, or that are lost to
follow-up prior to the 12-week primary endpoint, we will
use the BMI plus last value captured for the EAT-26 test as
a method of imputation of missing data.BMC Pediatrics 2008, 8:4 http://www.biomedcentral.com/1471-2431/8/4
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A student's t-test (assuming a normal distribution of the
measures; otherwise, Wilcoxon Mann-Whitney test will be
used) will be used in order to compute the change
between the EAT-26 and the difference in BMI from base-
line to week 12. If necessary, a linear regression model will
be fit to assess treatment effect adjusting for variables
thought to influence outcome that could result in imbal-
ance between treatment groups at baseline. Treatment
effect and its 95% confidence interval will be generated
for each primary outcome.
To examine secondary outcomes, the differences between
study groups will be assessed using Student's t-tests (as
described above for primary outcome). In order to avoid
multiple testing issues, results will be compared with an
alpha value adjusted for the number of tests performed
using the Bonferonni criterion.
Although the study is not powered to detect differences in
safety, we will nevertheless compare the frequency of
adverse events between the two study groups using chi-
square or Fisher's exact test.
Data Safety and Monitoring Committee
This study will be monitored by an independent DSMC
formed by the steering committee. The present DSMC
consists of three individuals who are not involved in this
research trial: a psychologist specializing in Mental Health
Research, an adolescent psychiatrist specializing in psy-
chopharmacology, and a pediatrician specializing in drug
trials (RCTs of chemotherapy in cancer patients). A statis-
tician who is blind to the treatment allocation will con-
duct a tabulation of safety data, and participants' baseline
characteristics after one year of recruitment. The commit-
tee will be made aware by the study coordinator of any
concerning side effects, and all data will be reviewed after
the enrollment of the tenth participant. Members of the
DSMC will also be responsible for developing terms of ref-
erence including clinical stopping rules and examples of
data presentation to be used for the tabulation of the data
for the safety analysis. The steering committee will be
notified by the DSMC only if the latter considers continu-
ance of the study to be unacceptable.
Interim analysis
One interim analysis will be run after the enrolment of the
33rd patient, which will be representative of half of the
sample. This analysis will focus on the primary outcome
and safety issues. Using the O'Brien-Fleming criteria for
two-sided test, the alpha-level of this interim analysis will
be 0.005. The final analysis will be conducted using an
alpha-level of 0.048.
Reporting
The Consolidated Standards of Reporting Trials (CON-
SORT) statement [37,38] will be used as a guideline for
the present clinical trial in order to assure high quality
reporting.
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